Work

Sintilimab plus IBI305 for hepatocellular carcinoma – Author's reply

Year: 2021

Type: letter

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(21)00479-4

Author: Jia Fan

Institutions: Fudan University, Zhongshan Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3198451736

Cites: 4

Cited by:

Related to: 10